Compare NRC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRC | IPSC |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 370.2M |
| IPO Year | 1997 | 2021 |
| Metric | NRC | IPSC |
|---|---|---|
| Price | $17.13 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 100.0K | ★ 1.4M |
| Earning Date | 04-27-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 4707.69 | 91.30 |
| EPS | ★ 50.00 | N/A |
| Revenue | ★ $119,686,000.00 | $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.35 | ★ N/A |
| Revenue Growth | 1.81 | ★ 1556.76 |
| 52 Week Low | $9.76 | $0.34 |
| 52 Week High | $22.79 | $2.97 |
| Indicator | NRC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 40.49 |
| Support Level | $14.78 | $1.81 |
| Resistance Level | $18.29 | $2.68 |
| Average True Range (ATR) | 0.91 | 0.25 |
| MACD | 0.15 | -0.08 |
| Stochastic Oscillator | 52.12 | 6.37 |
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.